文献速递心律失常

心房颤动患者口服抗凝治疗颅外出血的发生率与预测因素:COMBINE-AF 分析

Incidence and Predictors of Extracranial Bleeding on Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A COMBINE-AF Analysis.
PubMed 文献 · Circulation · 2026-08-04

该研究汇总 5 项房颤口服抗凝随机试验共 73 737 例患者,分析颅外临床相关出血的发生率、危险因素及人群归因分数。平均随访 705 天,颅外临床相关出血累积发生率为 26%,其中大出血为 7%,临床相关非大出血为 19%。基线协变量可解释 66% 至 69% 的人群归因出血风险。

要点

  • 房颤口服抗凝患者颅外临床相关出血累积发生率约 26%,远高于单纯大出血的 7%。
  • 消化道出血占大出血的 49%,是颅外大出血最常见部位。
  • 基线模型仅解释约三分之二的人群归因出血风险,存在未测量的出血影响因素。

核心结论

  • 房颤患者接受口服抗凝治疗时颅外临床相关出血常见,可能比单纯大出血更能反映总体出血负担。
  • 多变量模型中的基线协变量可解释 66% 至 69% 的人群归因出血风险。
  • 约三分之一的出血风险可能由未测量或未知因素贡献。

研究设计与样本

  • 研究类型为 5 项房颤口服抗凝随机试验的汇总分析,来源为 COMBINE-AF 协作。
  • 纳入 73 737 例接受直接口服抗凝药或华法林治疗的房颤患者。
  • 平均随访 705 天,主要结局为颅外临床相关出血。

主要发现

  • 73 737 例患者中有 10 634 例发生颅外临床相关出血,累积发生率为 26%(95% CI,18%–35%),每 100 人年 7.6 例。
  • 其中大出血 3188 例,累积发生率 7%(95% CI,6%–7%),每 100 人年 2.1 例。
  • 临床相关非大出血 7446 例,累积发生率 19%(95% CI,12%–28%),每 100 人年 5.2 例。
  • 消化道出血占临床相关出血的 26%,占大出血的 49%,占临床相关非大出血的 15%。
  • 不同出血严重程度类别的危险因素一致。

关键数值与推荐

  • 主要结局定义为首次发生颅外大出血或临床相关非大出血,依据国际血栓与止血学会标准。
  • 颅外临床相关出血累积发生率 26%(95% CI,18%–35%),每 100 人年 7.6 例。
  • 颅外大出血累积发生率 7%(95% CI,6%–7%),每 100 人年 2.1 例。
  • 颅外临床相关非大出血累积发生率 19%(95% CI,12%–28%),每 100 人年 5.2 例。
  • 人群归因分数:基线协变量解释出血风险的 66% 至 69%。

临床怎么用

  • 评估房颤口服抗凝患者的出血风险时,应关注颅外临床相关出血,而非仅关注大出血。
  • 消化道是颅外大出血的最常见部位,抗凝管理时应重视消化道出血风险。
  • 现有基线危险因素仅能解释约三分之二的出血风险,临床上仍需警惕未测量因素的影响。

局限性

  • 研究基于随机试验汇总数据,患者选择和治疗管理可能不同于真实世界人群。
  • 多变量模型中的基线协变量仅解释了 66% 至 69% 的人群归因出血风险,提示存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extracranial bleeding is the most common complication of oral anticoagulant (OAC) therapy for atrial fibrillation (AF), but its clinical importance for patients may be underrecognized. We sought to characterize extracranial bleeding events according to standardized severity definitions, identify baseline risk factors for bleeding, and quantify their population attributable fraction in patients with AF receiving OACs. METHODS: We analyzed patients receiving OACs from 5 pivotal randomized trials testing a direct OAC or warfarin in patients with AF (COMBINE-AF [A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation]). The primary outcome was extracranial clinically relevant bleeding, defined as a first episode of extracranial major or clinically relevant nonmajor bleeding according to International Society on Thrombosis and Haemostasis criteria. The Kaplan-Meier method was used to calculate the cumulative incidence of bleeding by category. Multivariable Cox regression models were used to estimate adjusted hazard ratios (HRs) with 95% CI. Logistic regression models were used to calculate average population attributable fraction with 95% CI. RESULTS: Of 73 737 patients treated with OACs, 10 634 experienced clinically relevant extracranial bleeding over a mean follow-up of 705 days (cumulative incidence, 26% [95% CI, 18%-35%]; 7.6 per 100 person-years). This included 3188 major bleeds (cumulative incidence, 7% [95% CI, 6%-7%]; 2.1 per 100 person-years) and 7446 clinically relevant nonmajor bleeds (cumulative incidence, 19% [95% CI, 12%-28%]; 5.2 per 100 person-years). The distribution of bleeding sites differed by severity, with gastrointestinal bleeds comprising 26% of clinically relevant bleeds, 49% of major bleeds, and 15% of clinically relevant nonmajor bleeds. Risk factors for extracranial bleeding were consistent across severity bleeding categories, and baseline covariates in our multivariable models accounted for 66% to 69% of the population attributable bleeding risk. CONCLUSIONS: Extracranial clinically relevant bleeding is common among patients with AF treated with OACs and may more accurately reflect the overall burden of bleeding than major bleeding alone. Our models explained about two-thirds of the average population attributable risk, suggesting that additional unmeasured or unknown factors contribute to bleeding risk.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Siegal, Carrier, Bahit, et al. Incidence and Predictors of Extracranial Bleeding on Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A COMBINE-AF Analysis. Circulation. 2026. PMID: 42549517. doi:10.1161/CIRCULATIONAHA.125.079205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。